Topaz Guy, Haisraely Ory, Shacham Yacov, Beery Gil, Shilo Lotan, Kassem Nuha, Pereg David, Kitay-Cohen Yona
Department of Internal Medicine C, Meir Medical Center, Kfar Saba, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Clin Cardiol. 2018 Apr;41(4):539-543. doi: 10.1002/clc.22925. Epub 2018 Apr 23.
Chest-pain patients deemed safe for discharge from internal medicine wards might still be at risk for adverse outcomes.
CHA DS -VASc score improves risk stratification of low-risk chest-pain patients discharged after acute coronary syndrome (ACS) rule-out.
We accessed medical records of patients who were admitted to internal medicine wards at a single medical center during 2010-2016 and discharged following an ACS rule-out. Patients were classified according to CHA DS -VASc score: 0-1 (low), 2-3 (intermediate), >3 (high). Primary endpoint was occurrence of ACS at 1 year; 30-day and 1-year all-cause mortality (ACM) were secondary outcomes.
Of 12 449 patients, 7057 (57%) had low, 3781 (30%) intermediate, and 1611 (13%) high CHA DS -VASc scores. Compared with a low score, intermediate and high scores were associated with significantly increased risk for 1-year ACS during the first year (OR: 2.89, 95% CI: 1.91-4.37, P < 0.01 and OR: 4.84, 95% CI: 3.02-7.74, P < 0.01, respectively). Each 1-point increase in CHA DS -VASc was associated with a 37% increased risk for 1-year ACS. A higher CHA DS -VASc score was associated with significantly higher 30-day ACM. Hazard ratios for 30-day ACM were 1.9 (95% CI: 1.1-3.4, P = 0.03) and 4.4 (95% CI: 2.4-7.9, P < 0.01) for intermediate and high CHA DS -VASc scores, respectively, compared with a low score. Each 1-point increase in CHA DS -VASc score was associated with 43% increased risk for 30-day mortality.
High CHA DS -VASc score (>3) was associated with adverse outcomes among chest-pain patients discharged from internal medicine wards following ACS rule-out.
被认为可安全从内科病房出院的胸痛患者仍可能面临不良结局风险。
CHA₂DS₂-VASc评分可改善急性冠状动脉综合征(ACS)排除后出院的低风险胸痛患者的风险分层。
我们查阅了2010年至2016年期间在单一医疗中心内科病房住院并在ACS排除后出院的患者的病历。患者根据CHA₂DS₂-VASc评分分类:0 - 1分(低风险)、2 - 3分(中风险)、>3分(高风险)。主要终点是1年时ACS的发生情况;30天和1年全因死亡率(ACM)为次要结局。
在12449例患者中,7057例(57%)CHA₂DS₂-VASc评分低,3781例(30%)评分中等,1611例(13%)评分高。与低评分相比,中等和高评分与第一年1年ACS风险显著增加相关(OR分别为:2.89,95%CI:1.91 - 4.37,P < 0.01;OR为:4.84,95%CI:3.02 - 7.74,P < 0.01)。CHA₂DS₂-VASc评分每增加1分,1年ACS风险增加37%。较高的CHA₂DS₂-VASc评分与30天ACM显著升高相关。与低评分相比,中等和高CHA₂DS₂-VASc评分的30天ACM风险比分别为1.9(95%CI:1.1 - 3.4,P = 0.03)和4.4(95%CI:2.4 - 7.9,P < 0.01)。CHA₂DS₂-VASc评分每增加1分,30天死亡率风险增加43%。
在ACS排除后从内科病房出院的胸痛患者中,高CHA₂DS₂-VASc评分(>3)与不良结局相关。